US Manufacturing Growth The California manufacturing expansion signals increased US supply capacity for ex vivo gene therapies, creating business development opportunities with transplant centers, contract manufacturers, logistics providers, and hospital systems to integrate manufacturing, supply chain, and patient access.

Europe Access Momentum European market activity includes Erkim Ilac collaborations and a Beneluxa reimbursement push for Libmeldy, presenting BD paths to map payer processes, engage regional centers of excellence, and structure access programs and pricing conversations.

Strategic Backing Kyowa Kirin’s acquisition brings global commercialization and development resources, enabling faster market penetration, potential cross-sell of Libmeldy with other portfolio therapies, and scaled manufacturing collaborations across regions.

HSC Therapy Focus Orchard’s emphasis on hematopoietic stem cell gene therapies for rare diseases invites partnerships with specialty clinics, research consortia, and patient advocacy groups, supporting early access programs and site expansion for clinical development.

Global Expansion Readiness Historical site expansions (including Fremont and now California) demonstrate a sustained commitment to capacity and geographic reach, creating opportunities to partner with US and international centers, supply chains, and regulatory teams for scale-up and market access.